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Introduction
In December 2019, in the Hubei province of China, an epi-
demic began sustained by a coronavirus named severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2). The
syndrome has been named coronavirus disease 2019
(COVID-19) and is characterized mainly by respiratory and
systemic symptoms (cough, rhinorrhea, fever, arthralgia, my-
algia, fatigue) [1]. The virus is transmitted during close con-
tact through respiratory droplets and by fomites. It rapidly
spread in the world, leading the World Health Organization
officially to declare a pandemic state on March 11, 2020.
The virus diffusion is favored by asymptomatic subjects or
patients with mild symptoms and by the long-time viral load
disappearance (14 days or maybe longer). COVID-19 seems
to have a lower mortality compared with other more important
human coronavirus syndromes (SARS-1 and MERS), but a
higher spread capability [1]. However, the disease could
evolve to a severe interstitial pneumonia requiring mechanical
ventilation; therefore, it is important to contain COVID-19
diffusion to avoid intensive care unit (ICU) saturation.
In Italy, the first case of secondary transmission was report-
ed on February 18, 2020 in Codogno (Lombardy, North Italy).
Since then, the virus spread in North regions and then quickly
in the entire Country, leading to 107,709 confirmed cases and
24,648 deaths (ht tp: / /www.salute .gov. i t /por ta le /
nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?
lingua=italiano&id=5351&area=nuovoCoronavirus&menu=
vuoto, last access April 22, 2020).
In order to contain the transmission, the Italian government
disposed a lockdown from March 8, 2020 in North Italy and
from March 11, 2020 in the rest of the country (still ongoing
during the writing of this paper). The lockdown consists in the
closing of all unnecessary activities and in the prohibition of
all the people to move between different cities and municipal-
ities, except for proven working needs and health reasons.
In Lombardy, the Italian regionmost hit from the epidemic,
the regional government suspended from March 8, 2020 all
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the deferrable and non-urgent clinical activities, with the pur-
pose to reduce inflow of in- and out-patients and to increase
the health care offer for COVID-19 patients, in terms of ca-
pacity of beds and number of hospital staff. All the health-care
system was needed to be rethought in order to guarantee also
non-COVID-19 patients assistance, especially for patients
with chronic diseases and requiring hospital treatment.
Scleroderma Unit of ASST Pini-CTO Hospital
The Department of Rheumatology of ASST Pini-CTO
Hospital in Milan includes some specialized Units such as
Early Arthritis Clinic, Lupus Clinic, Bone Unit, Sjögren
Clinic, and Scleroderma Unit.
The Scleroderma Unit follows more than 600 patients suf-
fering from systemic sclerosis (SSc). SSc is a rare systemic
disease characterized by inflammatory, vascular, and fibrotic
processes resulting in skin fibrosis and multiple organ mani-
festations, such as interstitial lung disease, pulmonary arterial
hypertension, and digital ulcers [2]. SSc treatment requires
both immune-modulating therapies for certain clinical mani-
festations and vascular therapies for microangiopathy. No
disease-modifying drugs for SSc exist; a close follow-up with
a regular screening of organ involvement in these patients
appears to improve mortality [3].
The Scleroderma Unit is a national referral center for this
rare connective tissue disease and also the Italian referral cen-
ter for autologous stem cell transplantation in SSc. Our pa-
tients are almost 60% from the North of Italy and 40% from
the rest of the country.
Our normal clinical activity is characterized by outpatient
visits, videocapillaroscopy exam, ulcers treatment (including
digital lipofilling), therapeutic infusions in day hospital regi-
men (prostanoids, intravenous biologic drugs, and immuno-
globulin), and clinical trials. Four physicians, four nurses, two
of whom specialized in ulcers advanced medications, and one
data manager for clinical trials are involved.
How to take care of SSc patients
in the COVID-19 era?
Great importance in the mortality associated with COVID-19
has been given to the concomitant comorbidities (diabetes,
hypertension, cardiovascular disease, lung disease, chronic
liver disease, and malignancies) of the patients, but no exten-
sive case series of COVID-19 in SSc patients are reported in
literature to date [4]. Since lung diseases and immunosuppres-
sion areWHO-defined risk factors for a more severe course of
COVID-19, SSc patients could represent a subgroup of pa-
tients at increased risk of respiratory or life-threatening
complications.
After COVID-19 outbreak and consequent regional and
national legislations, only urgent visits and therapeutic treat-
ments have been admitted in the Italian hospitals, including
the Gaetano Pini hospital. Then, we had to reorganize our
Scleroderma Unit in order to manage adequately all SSc pa-
tients, balancing the need to cure and the need to reduce the
risk of contagion.
Education
A good education of patients with SSc during the SARS-CoV-
2 outbreak was mandatory. Each patient has been invited to
follow WHO and Italian Ministry of Health recommenda-
tions: social distancing; frequent hand wash; use of masks
and gloves; and avoid touching nose, eyes and mouth.
We also gave patient answers and support regarding work-
ing issues, especially for SSc patients working in settings of
high-risk infection.
Home therapy management
All patients have been invited to maintain home therapies,
even the immunosuppressive treatments, unless the appear-
ance of symptoms was suggestive of an infectious disease.
The risk of dangerous disease flares after suspension of im-
munosuppressive treatment is high and should be avoided.
The Italian Society of Rheumatology (SIR) provided a reply
to frequently asked questions (FAQ) among rheumatic pa-
tients facing up COVID-19 that our Unit shared with SSc
patients (https://www.reumatologia.it/cmsx.asp?IDPg=1087).
Keep in contact
Using different ways of communication (phone call, email,
sharing of photos and files), we have assured an easy and
constant contact with SSc patients unable to reach the
Hospital, guiding them in the management of the disease,
from a clinical, therapeutic, and bureaucratic point of view.
The therapeutic continuity has been guaranteed through the
evaluation of laboratory and/or instrumental tests and symp-
toms reported by the patients.
During these contacts, we also have assessed the risk of
COVID-19 in SSc patients, investigating for the presence of
fever, cough, dyspnea, sore throat, rhinorrhea, fatigue, anos-
mia, and all the other typical symptoms of COVID-19 and
asking about known contacts with COVID-19 patients.
In Italy, dedicated numbers for sanitary assistance of
COVID-19 cases have been established; therefore, in the pres-
ence of symptoms indicative of moderate to severe COVID-
19 (dyspnea, desaturation), the patients have been invited to
call for assistance.
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Hospital reorganization
Since the first epidemic appearance in Italy, checkpoints have
been set up at hospitals and department entrances. A nurse
asks for symptoms suggestive of COVID-19 in the last
15 days, measures body temperature, and provides hand
sanitizer and surgical mask to the patients and personal staff,
reporting on a register names, dates, and time of entry. The
access is forbidden for caregivers, and outpatient visits are
scheduled in order to avoid overcrowding in waiting rooms.
Doctors, nurses, and all the hospital staff wear the proper
personal protective equipment (PPE) and follow the recom-
mendations to prevent contamination.
Day hospital infusions are organized in respect of the dis-
tance needed between patients (at least 2 m). SSc patients
living faraway from Lombardy who need infusion therapies
have been referred to their closest hospital, temporarily.
Ulcer medications
The service of ulcers and wound medication has been main-
tained for severe cases. SSc patients with ulcers who cannot
reach the Hospital, due to the lockdown, have been followed
as well, since our specialized nurses guided caregivers or
home nurse on the correct management, with the aid of video
calls and photos.
Hospital drug dispensation
Our Pharmacy, in accordance with territorial sanitary agencies
or pharmaceuticals companies, has organized home deliveries
of drugs only supplied by hospital pharmacies in Italy, such as
mycophenolate mofetil, macitentan, selexipag, and subcuta-
neous biologics.
Conclusion
The SARS-Cov-2 outbreak has led to a rapid reorganization of
Italian Public Health system to assure COVID-19 patients
assistance, with a conversion of a large number of hospitals
and clinics in COVID-19-specialized centers. Clinical
management of patients with chronic diseases included rheu-
matologic patients, which risk to be sacrificed in order to
respond to COVID-19 pressure. The organization of our
Scleroderma Unit has been quickly rethought to assure SSc
patients assistance in safety for them and health-care workers.
The use of electronic way of communication and a frequent
virtual contact with SSc patient have allowed a continuity of
care also outside the Hospital.
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